The efficacy of NRAS ASO-1 and NRAS ASO-2 was assessed in two NRAS-mutant melanoma cell lines at four time points, showing that the treatment can reduce NRAS-mRNA levels by up to 95%, with a peak depletion observed between 48 and 72 h. The gene discussed is NRAS; the disease is melanoma.